The Archive · 2 posts
Regenerative medicine revolution! 🌿 Tissue Regenix Group (TRX) on LSE leverages cutting-edge tech for tissue healing and transplant solutions. 💉
Tissue Regenix reports 6% H1 revenue decline to $13.8m but maintains positive adjusted EBITDA outlook and full-year profitability guidance.
September 8, 2025
Showing 1 of 2 posts
Tissue Regenix (TRX) posts record $1.9m EBITDA & 9% revenue growth. dCELL surges 23%. Board confident after shelving sale.
JoshuaJune 25, 2025